Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;67(8):1317-1324.
doi: 10.1007/s00262-018-2191-3. Epub 2018 Jun 26.

Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge

Luana Calabrò  1 , Aldo Morra  2 , Robin Cornelissen  3 , Joachim Aerts  3 , Michele Maio  4
Affiliations
Review

Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge

Luana Calabrò et al. Cancer Immunol Immunother. 2018 Aug.

Abstract

Treatment of malignant pleural mesothelioma (MPM) represents a highly unmet medical need. Here, we discuss the results and therapeutic potential of first- and second-generation immunomodulatory antibodies targeting distinct immune checkpoints for the treatment of MPM, as well as their prospective therapeutic role in combination strategies. We also discuss the role of appropriate radiological criteria of response for MPM and the potential need of ad hoc criteria of disease evaluation in MPM patients undergoing treatment with immunotherapeutic agents.

Keywords: Immune checkpoint; Immunotherapy; Mesothelioma; NIBIT-2016.

PubMed Disclaimer

Conflict of interest statement

Luana Calabrò served on the advisory board of Bristol Myers Squibb; Aldo Morra declares no conflict of interest; Robin Cornelissen served on advisory boards of Boehringer-Ingelheim, Roche, and Lilly; Joachim Aerts served on advisory boards of Eli-Lilly Bristol Myers Squibb, Roche-Genetech, Astra-Zeneca, MSD Sharp & Dohme, and Boehringer Ingelheim, and is a stock owner of Amphera Immunotherapy; Michele Maio served on advisory boards of Bristol Myers Squibb, Roche-Genentech, and AstraZeneca-MedImmune.

Figures

Fig. 1
Fig. 1
CT scan in axial plan (a–c) and multiplanar reformatting sagittal plane (d–f) of an MPM patient treated with tremelimumab and durvalumab and who achieved rapid PR. Tumour assessment was completed at baseline (a, d), W12 (b, e) and W24 (c, f). The patient achieved a rapid PR at W12 (b, e), persisting at W24 (c, f)
Fig. 2
Fig. 2
CT scan in axial plan of an MPM patient treated with tremelimumab and durvalumab and who had a mixed response. Tumour assessment was completed at baseline (a, c, e), W12 (b, d, f), W24 (g), and W36 (h). The patient achieved a PR for pleural lesions with the disappearance of two lesions (b, d) and an increase of a lesion in soft tissue (f) at W12. CT scan at W24 shows the persistent overall pleural PR and a significant decrease of the lesion in soft tissue (g), persisting at W36 (h)
Fig. 3
Fig. 3
CT scan in axial plan of an MPM patient treated with tremelimumab and who had a delayed objective response. Tumour assessment was completed at baseline (a), W6 (b), and W80 (c). The patient achieved a PR (c) at W80 after the initial PD at W6 (b)
See this image and copyright information in PMC

References

    1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716–724. doi: 10.2471/BLT.11.086678. - DOI - PMC - PubMed
    1. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5 suppl):v31–9. doi: 10.1093/annonc/mdv199. - DOI - PubMed
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644. doi: 10.1200/JCO.2003.11.136. - DOI - PubMed
    1. Zalcman G, Mazieres J, Margery J, Greillier R, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivièr F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414. doi: 10.1016/S0140-6736(15)01238-6. - DOI - PubMed
    1. Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(4):447–456. doi: 10.1016/S1470-2045(15)70056-2. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources